<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838405</url>
  </required_header>
  <id_info>
    <org_study_id>CT-388-101</org_study_id>
    <nct_id>NCT04838405</nct_id>
  </id_info>
  <brief_title>A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 1 Randomized, Double Blind, Placebo Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CT-388 in Otherwise Healthy Overweight and Obese Adult Participants and in Obese Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmot Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Carmot Australia First Pty Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Carmot Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human evaluation of CT-388 in a double blind, placebo controlled,&#xD;
      randomized, SAD/MAD/MD, safety, tolerance, PK, and PD study when administered as a SC&#xD;
      injection in otherwise healthy overweight and obese adult participants and obese participants&#xD;
      with T2DM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by self-report</measure>
    <time_frame>Baseline up to 6 weeks</time_frame>
    <description>Safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve (AUC)</measure>
    <time_frame>Baseline up to 6 weeks</time_frame>
    <description>PK AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observe drug concentration (Cmax)</measure>
    <time_frame>Baseline up to 6 weeks</time_frame>
    <description>PK Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life</measure>
    <time_frame>Baseline up to 6 weeks</time_frame>
    <description>PK t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean body weight</measure>
    <time_frame>Baseline up to 6 weeks</time_frame>
    <description>PD body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean glucose levels</measure>
    <time_frame>Baseline up to 6 weeks</time_frame>
    <description>PD glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean insulin levels</measure>
    <time_frame>Baseline up to 6 weeks</time_frame>
    <description>PD insulin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>CT-388</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC dose of CT-388</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SC dose of placebo matching CT-388 dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT-388</intervention_name>
    <description>Synthetic Peptide</description>
    <arm_group_label>CT-388</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females&#xD;
&#xD;
          -  18-65 years old, inclusive&#xD;
&#xD;
          -  BMI 27.0-40.0, inclusive&#xD;
&#xD;
          -  Stable body weight for 2 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant medical history&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  History of malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Elliott</last_name>
    <role>Study Director</role>
    <affiliation>Carmot Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Elliott</last_name>
    <phone>510-666-6328</phone>
    <email>melliott@carmot.us</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carmot Clinical Research Unit 102</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carmot Clinical Research Unit 101</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>https://carmot-therapeutics.us/</url>
    <description>Carmot Therapeutics, Inc.</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

